following an abbreviated submission:
romiplostim (Nplate) is accepted for restricted use within NHSScotland.
Indication under review: chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)
SMC restriction: to use in patients with severe symptomatic ITP or patients with a high risk of bleeding.
Romiplostim has previously been accepted for restricted use in adults with ITP. The licence has now been extended to use in children from the age of 1 year.
Download detailed advice358KB (PDF)
- Medicine name:
- romiplostim (Nplate)
- SMC ID:
- Chronic immune (idiopathic) thrombocytopenic purpura patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated submission
- Date advice published:
- 11 February 2019